Digestive System Neoplasms Clinical Trial
— EmoVie_K2Official title:
Effectiveness of an Educational Intervention Aimed at Increasing the Emotional Competencies of Patients Under Surveillance After Antineoplastic Treatment of Oesogastric or Bronchopulmonary Cancer: a Randomized, Multicenter, Controlled Pilot Study (EmoVie-K2)
Emotional skills are the ability to use emotions cleverly in daily life. Good emotional skills are associated with better mental and physical health in healthy and clinical populations. However, to our knowledge, cancer patients have never benefited from an intervention aiming at increasing their emotional skills. Our goal was thus to design and test such an intervention. A prospective, multi-center, randomized controlled trial (RCT) will be conducted in esogastric and lung cancer patients after antineoplastic treatments. Forty-three patients are expected in each arm. The primary outcome is the change in emotional skills assessed using a patient-reported validated questionnaire between the start and two weeks after the end of the intervention and at 2-month follow-up. The experimental arm will have to follow three individual sessions on emotional skills (i.e. identification, understanding, expression and regulation of emotions) while the control arm will have to follow three sessions of relaxation. In each arm, the first session can be held face to face or over the phone and the last two sessions will be held over the phone. Patients have exercises to practice in between sessions.It is hypothesised that the experimental group will experience a greater increase in emotional skills than the control group.
Status | Recruiting |
Enrollment | 86 |
Est. completion date | October 2023 |
Est. primary completion date | October 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patient under surveillance after curative or palliative antineoplastic treatment (surgery and/or chemoradiotherapy and/or radiotherapy alone and/or chemotherapy alone) of esogastric or bronchopulmonary cancer, - Patients with a life expectancy estimated by their physician involved in the research to be greater than or equal to six months, - Patient with a = 4 score on the Distress Scale (scale from 0 to 10), - Affiliation to a social security scheme, - Mastery of the French language, - Signing of informed consent to participate in this research. Exclusion Criteria: - Cognitive disorders or unstabilized psychiatric disorders that may impair the ability of reasoning and thinking necessary to complete the questionnaires and attend workshops - Difficulty or deficiency that prevent the patient from a good understanding of the imperatives of the research - Any situation likely to significantly affect emotional competence during the study according to the investigator's judgment (in particular, ongoing psychotherapeutic follow-up)) - Patients under judicial protection (guardianship or curators). |
Country | Name | City | State |
---|---|---|---|
France | Hôpital Calmette,CHU | Lille |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Lille | SCALab UMR CNRS 9193 |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in patient emotional skills from baseline to 15 days after the end of intervention | Variation in patient-reported 13-item Short Profile of Emotional Competence (S-PEC) score from baseline (T0) to 15 days after the intervention (T1) | Between Baseline (T0) and 15 days after the intervention (T1) | |
Secondary | Patient emotional skills at follow up | Variation in the emotional competence score (13-item S-PEC) between Baseline (T0) and T2 (2.5 months after the last session). | Between T0 (start of the intervention) and T2 (2 months after T1) | |
Secondary | Difficulties in Emotional Regulation | Variation in the Difficulties in Emotional Regulation Scale (DERS 16) score between T0 and T1 and between T1 and T2. | Between T0 (baseline) and T1 (15 days after the end of the intervention) and between T1 and T2 (2 months after T1) | |
Secondary | Quality of life by FACT-G | Patients' self-reported quality of life assessed using the Functional Assessment of Cancer Therapy - General (FACT-G) questionnaire | At T0 (before the first session), at T1 (15 days after the last session) and at T2 (2 months after T1). | |
Secondary | Change in quality of life using FACT-G | Variation in assessed quality of life (FACT-G) between T0 and T1 and between T1 and T2 based on variation in emotional competence (13-item S-PEC) | Between T0 (baseline) and T1 (&5 days after the end of the intervention) and between T1 and T2 (2 months after T1) | |
Secondary | Patient participation in workshops | The percentage of patients who have attended the 3 group sessions | Between 2 weeks and 2 months | |
Secondary | Patient adherence to exercises to do at home between sessions | The percentage of patients who have performed the suggested exercises at home between sessions | Between 2 weeks and 2 months | |
Secondary | Patient satisfaction | Patient-reported satisfaction regarding the intervention using ad hoc questionnaire | T1 (15 days after the end of the intervention) and T2 (2 months after T1) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06019702 -
Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen Alone in Subjects With Advanced Digestive System Neoplasms
|
Phase 1 | |
Recruiting |
NCT06026774 -
Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Subjects With Resected Digestive System Neoplasms
|
Phase 1 | |
Recruiting |
NCT06026800 -
Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Combination With Standard First-line Treatment in Subjects With Advanced Digestive System Neoplasms
|
Phase 1 | |
Completed |
NCT02909452 -
Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT05602935 -
Efficacy and Safety of SOX Regimen Combined With Camrelizumab as Neoadjuvant Treatment in Locally Advanced Gastric Cancer: a Phase II, Single-arm Study
|
Phase 2 | |
Recruiting |
NCT04518852 -
TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC
|
Phase 2 | |
Completed |
NCT03717298 -
Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma
|
Phase 2 | |
Recruiting |
NCT05322486 -
Palliative Primary Tumor Resection in Minimally Symptomatic Patients With Colorectal Cancer and Synchronous Unresectable Metastases
|
||
Terminated |
NCT03306693 -
Educational Intervention to Increase the Emotional Competence of Patients With Oesogastric and Bronchopulmonary Cancers
|
N/A | |
Active, not recruiting |
NCT01037049 -
Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks
|
Phase 2 | |
Recruiting |
NCT02208804 -
Surefire Infusion System vs. Standard Microcatheter Use During Holmium-166 Radioembolization
|
Phase 2/Phase 3 | |
Completed |
NCT04080843 -
Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC Patients
|
Phase 2 | |
Recruiting |
NCT03303495 -
A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC
|
Phase 3 | |
Terminated |
NCT04644315 -
A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors
|
Phase 2 | |
Recruiting |
NCT03271255 -
Apatinib Versus Bevacizumab in Second-line Therapy for Colorectal Cancer(ABST-C)
|
Phase 2 | |
Recruiting |
NCT03221335 -
EUS-guided RFA for Solid Abdominal Neoplasms
|
N/A | |
Recruiting |
NCT02487017 -
DC-CIK Combined With TACE in the Treatment of Hepatocellular Carcinoma
|
Phase 2 | |
Not yet recruiting |
NCT01556815 -
Sorafenib Combined With Transarterial Chemoembolization in Treating HBV-infected Patients With Intermediate Hepatocellular Carcinoma
|
Phase 2 | |
Recruiting |
NCT04949282 -
Spanish Series of Patients Treated With the Radionuclide Lutetium177
|
||
Completed |
NCT01964430 -
Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)
|
Phase 3 |